MTCR - Metacrine, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.5550 |
| Open | 0.5550 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.5510 - 0.5700 |
| 52 Week Range | 0.3030 - 0.5800 |
| Volume | |
| Avg. Volume | 78,208 |
| Market Cap | 24.985M |
| Beta (5Y Monthly) | -0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0400 |
| Earnings Date | May 29, 2023 - May 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
GlobeNewswireMetacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www
- GlobeNewswire
Metacrine Reports Third-Quarter 2022 Results
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d
BenzingaEquillium Buys Inflammatory Bowel Disease Player In All-Stock Deal
Equillium Inc (NASDAQ: EQ) has agreed to acquire Metacrine Inc (NASDAQ: MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. Earlier this year, Metacrine axed 50% of its workforce. Through the acquisition, Equillium adds Metacrine's farnesoid X receptor platform, including lead molecule MET642 for inflammatory bowel diseases. Equillium will be seeking
Business WireEquillium to Acquire Metacrine in All-Stock Transaction
LA JOLLA, Calif., September 06, 2022--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. The transaction has been approved by the boards of directors of bot
- GlobeNewswire
Metacrine Reports Second-Quarter 2022 Results
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. “We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic altern